68 studies on Ghk-cu curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 5,085 published Ghk-cu COA source records from third-party laboratories, covering 1,337 publicly attributable vendor identities. Across 4,551 records with positive numeric purity, the arithmetic mean is 99.66%. 12 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 13 positive purity results are below 90%; 440 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 g | $21.00 | $21.00–$21.00 | Not available | 1 source · 1 offer |
| 50 mg | $6.38 | $5.00–$8.50 | $0.13 | 4 sources · 4 offers |
| 100 mg | $8.75 | $7.00–$10.50 | $0.09 | 4 sources · 4 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T01:49:34.747069+00:00. Calculation time is not a laboratory observation date.
Within that total, 1309 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 62 | 99.79% | 0 of 52 (0.0%) 0 0% / not detected · 0 wrong compound · 10 unclassified | Reveal with Pro → | |
| #2 | 38 | 99.77% | 0 of 38 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 57 | 99.86% | 1 of 57 (1.8%) 1 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120385 (99.91%) · #120384 (99.87%) · #120446 (99.95%) · #120332 (99.83%) · #120412 (99.97%) · #120219 (99.2%)
This theoretical study provides a fundamental understanding of the copper-GHK binding mechanism, which is essential for comprehending the peptide's biological functions. The detailed insights into the coordination geo…
This innovative co-assembly approach represents a significant breakthrough, opening a new avenue for the construction of diverse hybrid nanostructures using readily available and biocompatible biomolecules. The creati…
This study validates a bacterial fermentation method as a viable alternative to chemical synthesis for producing functional GHK, potentially lowering production costs. For users interested in GHK-Cu, this research pro…
This research significantly advances our understanding of how GHK and cis-urocanic acid function within the human body, particularly concerning their interactions with copper. The discovery of the [GHK][Cu(II)][cis-ur…
This research highlights the critical role of the delivery vehicle in determining the therapeutic efficacy of peptides like GHK-Cu. For individuals using peptides for wound care, this suggests that the formulation is …
The discovery of this potent synergy between GHK-Cu and hyaluronic acid represents a significant advancement in anti-aging technology, offering a novel and highly effective strategy for enhancing skin health. By demon…
This research provides a valuable, non-toxic method for significantly enhancing laccase production using GHK-Cu as an inducer, addressing safety concerns associated with traditional inducers. The use of a GHK-chelated…
This research presents a highly selective and efficient fluorescent sensor for Cu(II) ions, which holds significant implications for the biotech and peptide community. The ability to accurately and selectively detect …
This study provides compelling evidence that GHK-Cu holds significant promise as a novel therapeutic agent for Alzheimer's disease. Its ability to simultaneously improve cognitive function, reduce amyloid pathology, a…
This research represents a pivotal advancement in peptide delivery technology, effectively overcoming the significant challenges of peptide instability and poor bioavailability under harsh conditions. The development …
This research highlights GHK's potential as a powerful cytoprotective compound against metal-induced damage, which is a significant contributing factor in neurodegenerative diseases. Its multifaceted ability to preven…
This research provides compelling evidence that GHK-Cu could serve as a novel and effective therapeutic agent for silicosis, a disease with a high incidence and no current specific treatment options. By targeting PRDX…
This research highlights the significant potential of GHK-Cu-loaded hydroxyapatite microspheres as a dual-action injectable filler. The sustained release of GHK-Cu combined with the structural support of HA offers a p…
If successful, this Phase 2 study could provide crucial evidence supporting GHK-Cu Gel as a novel and effective treatment to accelerate acute skin wound healing. This could significantly improve patient outcomes by re…
Free, no account — handy when you're working with Ghk-cu.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account